PBYI Stock Recent News
PBYI LATEST HEADLINES
Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Does Puma Biotech (PBYI) have what it takes to be a top stock pick for momentum investors? Let's find out.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.
Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here are four top-performing liquid stocks, Netflix (NFLX), Oceaneering International (OII), Puma Biotechnology (PBYI) and GigaCloud (GCT) which investors can add to their portfolio to boost returns.
Many of the world's major fashion brands are failing to combat forced labor in their supply chains, according to a new report.
Penny stocks are generally defined as stocks that trade for less than $5 per share. Low-priced stocks appeal to investors who can wait for these stock prices to appreciate.
Puma Biotech (PBYI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Puma Biotech (PBYI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.